Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
Status:
Completed
Trial end date:
2021-05-21
Target enrollment:
Participant gender:
Summary
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with
40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin
using soft mist inhaler in the treatment of critically ill patients with COVID-19
(coronavirus disease of 2019) induced ARDS (acute respiratory distress syndrome). The
patients will be assigned in a 1:1 ratio to receive standard treatment protocol plus inhaled
Low molecular weight heparin. The primary objective is to determine the hypoxemia improvement
on a 5-point clinical scale for COVID-19 induced ARDS patients.